This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
MiMedx (MDXG) delivered earnings and revenue surprises of +66.67% and +10.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?
by Zacks Equity Research
MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MiMedx (MDXG) Q1 Earnings Match Estimates
by Zacks Equity Research
MiMedx (MDXG) delivered earnings and revenue surprises of 0% and 2.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
BioHarvest Sciences Inc. (BHST) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioHarvest Sciences Inc. (BHST) delivered earnings and revenue surprises of -41.67% and 1.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
MiMedx (MDXG) Q4 Earnings Meet Estimates
by Zacks Equity Research
MiMedx (MDXG) delivered earnings and revenue surprises of 0% and 6.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
MiMedx (MDXG) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
by Zacks Equity Research
MiMedx (MDXG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in MiMedx (MDXG) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, MiMedx (MDXG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
How Much Upside is Left in MiMedx (MDXG)? Wall Street Analysts Think 37.12%
by Zacks Equity Research
The mean of analysts' price targets for MiMedx (MDXG) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MiMedx (MDXG) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
MiMedx (MDXG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can MiMedx (MDXG) Climb 77.92% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 77.9% upside potential for MiMedx (MDXG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
MiMedx (MDXG) delivered earnings and revenue surprises of 40% and 3.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
MiMedx Group (MDXG) Soars: Stock Adds 11.2% in Session
by Zacks Equity Research
MiMedx Group (MDXG) shares rose more than 11% in the last trading session, amid huge volumes.
Are Options Traders Betting on a Big Move in MiMedx Group (MDXG) Stock?
by Zacks Equity Research
Surging implied volatility makes MiMedx Group (MDXG) stock lucrative to the option traders.
MiMedx Group (MDXG) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
MiMedx Group (MDXG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
MiMedx Group (MDXG) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
MiMedx Group (MDXG) was a big mover last session, as the company saw its rise over 6% on the day amid huge volumes.
MiMedx Group (MDXG) Catches Eye: Stock Jumps 8.5% in Session
by Zacks Equity Research
MiMedx Group, Inc. (MDXG) moved big last session, as its shares rose above 8% on the day.
Falling Earnings Estimates Signal Weakness Ahead for MiMedx Group (MDXG)
by Zacks Equity Research
MiMedx Group (MDXG) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.
Why MiMedx Group (MDXG) Could Be Positioned for a Slump
by Zacks Equity Research
While MiMedx Group (MDXG) may not be a good pick right now, you can consider other stocks in the same industry.
Can MiMedx (MDXG) Double Despite FDA Investigation?
by David Bartosiak
Momentum Strategist David Bartosiak discusses MiMedx (MDXG) and the FDA investigation.